Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease

Diabetes increases the risk of liver disease progression and cirrhosis development in patients with nonalcoholic steatohepatitis (NASH). The association between diabetes and the risk of hepatocellular carcinoma (HCC) in NASH patients with cirrhosis is not well quantified. All patients with the diagnosis of NASH cirrhosis seen at Mayo Clinic Rochester between January 2006 and December 2015 were identified. All adult liver transplant registrants with NASH between 2004 and 2017 were identified using the United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation registry for external validation. Cox proportional hazard analysis was performed to investigate the association between diabetes and HCC risk. Among 354 Mayo Clinic patients with NASH cirrhosis, 253 (71%) had diabetes and 145 (41%) were male. Mean age at cirrhosis evaluation was 62. During a median follow‐up of 47 months, 30 patients developed HCC. Diabetes was associated with an increased risk of developing HCC in univariate (hazard ratio [HR] = 3.6; 95% confidence interval [CI] = 1.1‐11.9; P = 0.04) and multivariable analysis (HR = 4.2; 95% CI = 1.2‐14.2; P = 0.02). In addition, age (per decade, HR = 1.8; 95% CI = 1.2‐2.6; P < 0.01) and low serum albumin (HR = 2.1; 95% CI = 1.5‐2.9; P < 0.01) were significantly associated with an increased risk of developing HCC in multivariable analysis. Other metabolic risk factors, including body mass index, hyperlipidemia, and hypertension, were not associated with HCC risk. Among UNOS NASH registrants (N = 6,630), 58% had diabetes. Diabetes was associated with an increased risk of developing HCC in univariate (HR = 1.4; 95% CI = 1.1‐1.8; P < 0.01) and multivariable (HR = 1.3; 95% CI = 1.0‐1.7; P = 0.03) analysis. Conclusion: Diabetes is associated with an increased risk of HCC in patients with NASH cirrhosis.

[1]  V. Castranova,et al.  Beyond apoptosis of JNK1 in liver cancer , 2009, Cell cycle.

[2]  N. Kawada,et al.  The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease , 2020, International journal of molecular sciences.

[3]  M. Karin,et al.  Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Gores,et al.  Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  E. Bugianesi,et al.  Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease , 2016, PloS one.

[6]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[7]  A. Gasbarrini,et al.  Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk , 2015, Gastroenterology research and practice.

[8]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[9]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[10]  M. Manns,et al.  Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus , 2008, Hepatology.

[11]  M. Crossley,et al.  Observational Research Methods , 1987 .

[12]  C. Mann,et al.  Observational research methods. Research design II: cohort, cross sectional, and case-control studies , 2003, Emergency medicine journal : EMJ.

[13]  C. Byrne,et al.  Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis-implications for surveillance and future pharmacotherapy. , 2020, Hepatobiliary surgery and nutrition.

[14]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[15]  Zhiwen Liu,et al.  Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta‐analysis , 2012, Diabetes/metabolism research and reviews.

[16]  T. Therneau,et al.  Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. , 2012, Mayo Clinic proceedings.

[17]  W. Kim,et al.  De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era , 2018, Hepatology.

[18]  W. Kim,et al.  Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis , 2016, The American Journal of Gastroenterology.

[19]  Giorgio Saracco,et al.  The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011, Hepatology.

[20]  Puneet Puri,et al.  Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  A. Boonstra,et al.  NAFLD‐Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse , 2020, Hepatology.

[22]  O. Ohara,et al.  Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC , 2018, Cell.

[23]  Michael Karin,et al.  A central role for JNK in obesity and insulin resistance , 2002, Nature.

[24]  T. Joh,et al.  Albumin Suppresses Human Hepatocellular Carcinoma Proliferation and the Cell Cycle , 2014, International journal of molecular sciences.

[25]  G. Gores,et al.  Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study , 2017, Journal of clinical gastroenterology.

[26]  L. Carbone,et al.  Incidence of altered glucose tolerance in liver cirrhosis. , 1993, Diabetes research and clinical practice.

[27]  E. Wagner,et al.  Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. , 2008, The Journal of clinical investigation.

[28]  B. Graubard,et al.  Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States , 2013, The American Journal of Gastroenterology.

[29]  B. Carr,et al.  Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma , 2017, Oncology.

[30]  B. Naini,et al.  Metabolic factors affecting hepatocellular carcinoma in steatohepatitis , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[31]  S. Altekruse,et al.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[33]  T. Therneau,et al.  Factors that affect risk for hepatocellular carcinoma and effects of surveillance. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  Shelly C. Lu,et al.  NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances , 2018, The American Journal of Gastroenterology.

[35]  G. Ioannou,et al.  Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis , 2018, PloS one.

[36]  H. El‐Serag,et al.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  J. Samet,et al.  Fasting serum glucose level and cancer risk in Korean men and women. , 2005, JAMA.

[38]  S. Asch,et al.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[39]  H. El‐Serag,et al.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  S. Satapathy,et al.  Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . , 2020, Translational gastroenterology and hepatology.

[41]  J. Shieh,et al.  Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies , 2012, Gut.

[42]  Robert A Fisher,et al.  Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C , 2006, Hepatology.

[43]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[44]  E. Tapper,et al.  Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study , 2018, British Medical Journal.

[45]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[46]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[47]  Kuo-Chin Huang,et al.  Diabetes and hepatocellular carcinoma risks in patients with nonalcoholic steatohepatitis related cirrhosis. , 2020, Hepatobiliary surgery and nutrition.